Crisaborole

CAS 906673-24-3 11 current recordsSmall Molecule

Who holds supplier records for Crisaborole? 11 organisations hold a current record for Crisaborole: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (6), China (3), Italy (1) and Netherlands (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Crisaborole: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/crisaborole

Reading the evidence

  • 11 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Crisaborole expires 20 Jul 2030. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (11)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Crisaborole. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Crisaborole sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Crisaborole). The latest listed patent expires 20 Jul 2030. The latest listed exclusivity ended 3 Apr 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Crisaborole is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL484785).

Chemical identity

IUPAC name
4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
Canonical SMILES
B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
InChIKey
USZAGAREISWJDP-UHFFFAOYSA-N
Synonyms
AN-2728, AN2728, Crisaborol, Crisaborole, Eucrisa, Staquis, AN 2728, Crisaborole topical ointment 2%, CHEBI:134677, crisaborolum, RefChem:58963, D11AH06

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Phosphodiesterase 4 Inhibitor
Mechanism of action
Phosphodiesterase 4 Inhibitors

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Crisaborole?

11 organisations hold an active US FDA Type II Drug Master File or a CEP for Crisaborole: ANHUI POLY PHARM CO LTD (China), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CHANGZHOU PHARMACEUTICAL FACTORY (China), HONOUR LAB LTD (India), Jiangxi Synergy Pharmaceutical Co., Ltd (China), Macleods Pharmaceuticals Ltd. (India), MSN LIFE SCIENCES PRIVATE LIMITED (India) and OLON SPA (Italy), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Crisaborole Drug Master Files are active?

ANHUI POLY PHARM CO LTD (DMF 39148), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 33218), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 37356), HONOUR LAB LTD (DMF 33060), Jiangxi Synergy Pharmaceutical Co., Ltd (DMF 40025), Macleods Pharmaceuticals Ltd. (DMF 34506), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 33278) and OLON SPA (DMF 34234) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Crisaborole?

Yes. The latest patent listed for an approved US product containing Crisaborole expires 20 Jul 2030, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Crisaborole supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Crisaborole?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.